Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora \u00ae Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces FDA Approval of Wynzora\u00ae Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"EPI Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA\u00ae Cream, in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$18.0 million","newsHeadline":"Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora\u00ae Cream for Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Breakthrough Discovery With the Potential to Help Millions of People Suffering From Urea Associated Skin Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"EPI Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA\u00ae (calcipotriene and betamethasone dipropionate) Cream, 0.005%\/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"Hyphens Pharma licenses Wynzora\u00ae Cream for ASEAN countries from MC2 Therapeutics","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"DENMARK","productType":"Small molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by MC2 Therapeutics

    Menu

    MC2 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MC2 Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

              Details:

              Through the license agreement, MC2 will gain the commercialization rights for Wynzora consisting of Calcipotriene and Betamethasone dipropionate. It is an approved product indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older.

              Lead Product(s): Calcipotriol,Betamethasone Dipropionate

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Hyphens Pharma

              Deal Size: $2.7 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 12, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial

              Details:

              MC2-25, a first-in-class di-peptide drug candidate functioning as an effective isocyanate scavenger, is presently undergoing Phase II clinical trial evaluation for the treatment of Chronic Kidney Disease-associated Pruritus.

              Lead Product(s): MC2-25 CKD

              Therapeutic Area: Dermatology Product Name: MC2-25 CKD

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus

              Details:

              MC2-25 VLS is a first-in-class drug candidate for urea associated skin diseases using a di-peptide as an iso-cyanate scavenger to inhibit carbamylation of amino acids and proteins in the skin.

              Lead Product(s): MC2-25 VLS

              Therapeutic Area: Dermatology Product Name: MC2-25 VLS

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Co...

              Details:

              WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.

              Lead Product(s): Calcipotriol,Betamethasone Dipropionate

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: EPI Health

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces Initiation of a Phase 2 Clinical Trial in CKD-aP

              Details:

              MC2-25 Cream is an effective isocyanate scavenger showing >90 % inhibition of protein carbamylation and counteracting the morphological skin changes induced by carbamylation as demonstrated in an in vitro reconstructed human uremic skin model.

              Lead Product(s): MC2-25

              Therapeutic Area: Dermatology Product Name: MC2-25

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces Breakthrough Discovery With the Potential to Help Millions of People Suffering From Urea Associated Skin Diseases

              Details:

              MC2-25 CKD-aP is formulated to be highly tolerable, moisturizing, convenient to use and it quickly absorbs into the skin allowing patients to get on with their life and their daily routines.

              Lead Product(s): MC2-25

              Therapeutic Area: Dermatology Product Name: MC2-25

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Almirall and MC2 Therapeutics Ink Collaboration for European Rights to Wynzora® Cream for Plaque Psoriasis

              Details:

              In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.

              Lead Product(s): Calcipotriol,Betamethasone Dipropionate

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Almirall

              Deal Size: Undisclosed Upfront Cash: $18.0 million

              Deal Type: Collaboration February 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US

              Details:

              Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US. WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in chronic inflammatory conditions.

              Lead Product(s): Calcipotriol,Betamethasone Dipropionate

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: EPI Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 24, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces FDA Approval of Wynzora® Cream (calcipotriene and betamethasone dipropionate) for Adults with Plaque Psoriasis

              Details:

              The FDA approval is based on the results of the US Phase 3 clinical trial1 against active comparator Taclonex® Topical Suspension (calcipotriene and betamethasone dipropionate.

              Lead Product(s): Calcipotriol,Betamethasone

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              MC2 Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MC2 Therapeutics Announces Submission of Marketing Authorization Application in EU for Wynzora ® Cream

              Details:

              The MAA is supported by two comprehensive Phase 3 trials1 including a trial conducted in EU evaluating the efficacy and safety of Wynzora® Cream compared to vehicle and active comparator Dovobet/Daivobet® Gel in patients with psoriasis vulgaris.

              Lead Product(s): Calcipotriol,Betamethasone

              Therapeutic Area: Dermatology Product Name: Wynzora

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 16, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY